Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Momenta/Sandoz Tie-Up Adds Momentum to Large Molecules

This article was originally published in Start Up

Executive Summary

The July 2006 alliance between Momenta Pharmaceuticals and Novartis AG's generics outfit Sandoz underscores the role sugar characterization technologies may play in both copying complex molecules like follow-on biologics and improving on existing glycoproteins and complex mixtures.

You may also be interested in...



Ambrx Takes Advantage of Large Molecule Frenzy

Ambrx $52 million July 2006 Series C financing underscores recent increased interest in second-generation protein technologies and suggests that interest comes from an ever-wider group of investors.

The Large Molecule Future

In an extraordinary series of deals, Pharma has embraced early-stage large-molecule technology, reflecting both the surging value of biologics and the severity of pipeline anemia. But many observers are skeptical the less experienced Big Pharmas can buy themselves into a brand new business with very different requirements. For start-ups, however, the news is very good--they now have two clear and viable pathways to creating shareholder value: acquisition and alliance.

A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric

The press release was foggy; Sandoz Inc., the generics unit of Novartis AG, was teaming up with a biotech, Momenta Pharmaceuticals Inc. to commercialize "complex pharmaceutical products." Upon closer examination, the deal in fact has wide-ranging implications, representing the very real near-term possibility of a true generic biologic,

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141925

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel